文献速递食管与纵隔外科

淋巴结阳性食管鳞癌术后辅助化疗改善生存

Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival.
PubMed 文献 · Ann Thorac Surg · 2021-10-06

该回顾性队列研究纳入2013至2017年在河南省肿瘤医院接受食管切除术的淋巴结阳性食管鳞癌患者,经倾向评分匹配后比较辅助化疗与单纯手术的生存差异。结果显示辅助化疗组中位总生存54.0个月,显著优于单纯手术组28.0个月(P < .001),中位无病生存亦显著延长(33.0个月 vs 22.0个月,P = .007)。

要点

  • 淋巴结阳性食管鳞癌术后辅助化疗显著延长中位总生存(54.0 vs 28.0个月)。
  • 辅助化疗亦显著改善中位无病生存(33.0 vs 22.0个月)。
  • 多因素分析中辅助化疗与死亡风险降低显著相关。

核心结论

  • 术后辅助化疗改善淋巴结阳性食管鳞癌切除患者的总生存和无病生存。

研究设计与样本

  • 回顾性队列研究,选取2013至2017年郑州大学附属肿瘤医院(河南省肿瘤医院)接受食管切除术的食管癌患者。
  • 5118例接受食管切除术的患者中792例淋巴结阳性患者纳入研究,经1:1倾向评分匹配后辅助化疗组253例、单纯手术组253例。

主要发现

  • 辅助化疗组中位总生存54.0个月(95% CI,41.1-66.9个月),单纯手术组28.0个月(95% CI,22.4-33.6个月),P < .001。
  • 辅助化疗组中位无病生存33.0个月(95% CI,20.8-45.2个月),单纯手术组22.0个月(95% CI,17.0-27.0个月),P = .007。
  • 多因素分析中接受辅助化疗与死亡风险降低显著相关(P < .001),清扫超过6个淋巴结站与死亡风险降低边缘相关(P = .05)。

临床怎么用

  • 对食管鳞癌切除术后淋巴结阳性的患者,可考虑行辅助化疗以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the survival benefits of adjuvant chemotherapy in patients with positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma. METHODS: Patients who underwent esophagectomy for esophageal cancer in the Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) in Zhengzhou, China from 2013 to 2017 were selected for this retrospective cohort study. Patients with positive lymph nodes were grouped into the surgery alone group or the adjuvant chemotherapy group. Propensity score matching (1:1) was used to minimize baseline differences. RESULTS: Among the 5118 patients who underwent esophagectomy, 792 patients were enrolled in the study. After matching, 253 (of 476) patients (adjuvant chemotherapy group) and 253 (of 316) patients (surgery alone group) were included. The median overall survival was significantly prolonged in the adjuvant chemotherapy group (54.0 months; 95% CI, 41.1-66.9 months) compared with the surgery alone group (28.0 months; 95% CI, 22.4-33.6 months) (P < .001). A significant difference was also observed in median disease-free survival between the 2 groups (adjuvant chemotherapy group, 33.0 months [95% CI, 20.8-45.2 months] compared with the surgery alone group, 22.0 months [95% CI, 17.0-27.0 months]; P = .007). In a multivariable analysis, receiving adjuvant chemotherapy (P < .001) was significantly associated with a reduced risk of death, and dissection of more than 6 lymph node stations (P = .05) was marginally associated with a reduced risk of death. CONCLUSIONS: Postoperative adjuvant chemotherapy improves the overall survival and disease-free survival of patients with resected esophageal squamous cell carcinoma with positive lymph nodes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Feng SK, Liu XB, Xing WQ, et al. Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival. Ann Thorac Surg. 2021. PMID: 34626616. doi:10.1016/j.athoracsur.2021.08.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。